Advanced search
Publication Cover
Acta Cardiologica Volume 62, 2007 - Issue 1
Submit an article Journal homepage
3
Views
0
CrossRef citations to date
0
Altmetric
Articles

Systemic amyloidosis: a clinical challenge

Massimiliano PinelliDepartment of Internal Medicine IV, Azienda Ospedaliera-Universitaria Pisana, Pisa, Italy.
,
Massimo BindiDepartment of Internal Medicine IV, Azienda Ospedaliera-Universitaria Pisana, Pisa, Italy.Correspondence[email protected]
&
Maido CastiglioniDepartment of Internal Medicine IV, Azienda Ospedaliera-Universitaria Pisana, Pisa, Italy.
Pages 51-53 | Received 18 Apr 2006, Accepted 03 Aug 2006, Published online: 23 May 2017

References

  • Pepys MB. Amyloidosis. Annu Rev Med 2006; 57: 223–41.
  • Jessup M, Brozena S. Heart failure. N Engl J Med 2003; 348: 2007–18.
  • Gaasch WH, Zile MR. Left ventricular diastolic dysfunc-tion and diastolic heart failure. Annu Rev Med 2004; 55: 373–94.
  • Aurigemma GP, Gaasch WH. Diastolic heart failure. N Engl J Med 2004; 351: 1097–105.
  • Maredia N, Ray SG. Cardiac amyloidosis. Clin Med 2005; 5: 504–9.
  • Berk JL. Pleural effusions in systemic amyloidosis. Curr Opin Pulm Med 2005; 11: 324–8.
  • Falk RH, Comenzo RL, Skinner M. The systemic amyloi-doses. N Engl J Med 1997; 337: 898–909.
  • Kyle RA, Linus A, Beard CM, Linke RP, Gertz MA, O’Fallon WM, Kurland LT. Incidence and natural history of primary systemic amyloidosis in Olmsted county, Minnesota, 1950 through 1989. Blood 1992; 79: 1817–22.
  • Falk RH. Diagnosis and management of the cardiac amy-loidoses. Circulation 2005; 112: 2047–60.
  • Falk RH, Reisinger J, Dubrey SW, Mendes LA, San-chorawala V, Ekery D, Comenzo R, Vosburgh E, Skinner M. The effect of cardiac involvement on the outcome of intravenous melphalan therapy and autologous stem cell rescue for AL amyloidosis. In: Kyle RA, Gertz MA eds. Amyloid and the amyloidoses: VIHth international sympo-sium on amyloidosis. Rochester, Minnesota: Parthenon; 1998: 181-3.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Novo Nordisk – Driving change to defeat serious chronic diseases.
A bold vision to stop cardiovascular disease from being a leading cause of death.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.